Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03106779 · OUTCOME

PK Parameter: CL/F for Asciminib

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs · Source last updated 2026-08-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
L/hr
Interval / dispersion
Full Range
Time frame
Week 2 day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose

What was measured

Total apparent body clearance of drug from the plasma after oral administration (volume x time-1).

Analysis population: Participants in the Pharmacokinetic analysis set (PAS) with an available value for the outcome measure. PAS included all participants who provided at least one evaluable PK concentration of asciminib.

Groups in this outcome

Asciminib

Participants randomized to asciminib 40mg BID

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Asciminib14

Reported measurements

Source class 1
Values in L/hr · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Asciminib7.29Not reported3.7311.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3.73
        upper Limit
        11.5
        value
        7.29
denoms
  1. counts
    1. group Id
      OG000
      value
      14
    units
    Participants
description
Total apparent body clearance of drug from the plasma after oral administration (volume x time-1).
dispersion Type
Full Range
groups
  1. description
    Participants randomized to asciminib 40mg BID
    id
    OG000
    title
    Asciminib
param Type
MEDIAN
population Description
Participants in the Pharmacokinetic analysis set (PAS) with an available value for the outcome measure. PAS included all participants who provided at least one evaluable PK concentration of asciminib.
reporting Status
POSTED
time Frame
Week 2 day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose
title
PK Parameter: CL/F for Asciminib
type
SECONDARY
unit Of Measure
L/hr

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice